Dwight Oliver
A5017696294- Cancer, Hypoxia, and Metabolism
- Acute Myeloid Leukemia Research
- Glioma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- RNA modifications and cancer
- Molecular Biology Techniques and Applications
- Genetic factors in colorectal cancer
- Bacteriophages and microbial interactions
- Medical Imaging Techniques and Applications
- SARS-CoV-2 and COVID-19 Research
- Cancer Genomics and Diagnostics
- Sarcoma Diagnosis and Treatment
- Epigenetics and DNA Methylation
- Biosensors and Analytical Detection
- SARS-CoV-2 detection and testing
- Lymphoma Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Abdominal Surgery and Complications
- Mitochondrial Function and Pathology
- Multiple Myeloma Research and Treatments
- Head and Neck Cancer Studies
- Cutaneous lymphoproliferative disorders research
- Ear and Head Tumors
- Oral and Maxillofacial Pathology
- Vascular Malformations and Hemangiomas
The University of Texas Southwestern Medical Center
2016-2025
Southwestern Medical Center
2014-2024
VA North Texas Health Care System
2016
Texas Health Dallas
2010
The University of Texas Health Science Center at Houston
1997-2009
Baylor College of Medicine
2008
Committee on Publication Ethics
2005
Texas A&M University
2004-2005
Johns Hopkins University
2002
Johns Hopkins Hospital
2000
Purpose Proton magnetic resonance spectroscopy (MRS) of the brain can detect 2-hydroxyglutarate (2HG), oncometabolite produced in neoplasms harboring a mutation gene coding for isocitrate dehydrogenase ( IDH). We conducted prospective longitudinal imaging study to determine whether quantitative assessment 2HG by MRS could serve as noninvasive clinical biomarker IDH-mutated gliomas. Patients and Methods was performed 136 patients using point-resolved at 3 T parallel with standard assessment....
Background: Mesenteric venous hypertension and subsequent gut edema play a pivotal role in the development of intra-abdominal hypertension. Although is one cause hypertension, its impact on function unknown. The purpose this study was to create model acute hydrostatic evaluate effect motility barrier function. Methods: first study, group A, evaluated transit over time using 20 mL/kg 0.9% saline. second B, focused 12-hour period 80 Rats were randomized superior mesenteric vein partial...
Rosai–Dorfman disease (RDD) is an uncommon histiocytic proliferative disorder that can present in nodal, extranodal, or, extremely rarely, central nervous system (CNS)‐restricted form. RDD characterized histologically as a non‐Langerhans cell histiocytosis composed of atypical CD68 + /S‐100 /CD1a – macrophages demonstrating prominent emperipolesis and effacement the surrounding tissue. Previously thought to represent reactive process, recent studies have raised possibility other lesions,...
Abstract In patients with non–small cell lung cancer (NSCLC), the relationship between tumor metabolism and clinical outcomes is unknown. Here, 13C-labeled nutrients were intraoperatively infused into more than 90 surgically resectable pulmonary lesions, metabolic properties of resected tumors correlated survival. NSCLCs 13C-glucose, high 13C enrichment in tricarboxylic acid (TCA) cycle intermediates conferred a HR 3.8 for early death, typically metastasis. To test whether these features...
<div>Abstract<p>In patients with non–small cell lung cancer (NSCLC), the relationship between tumor metabolism and clinical outcomes is unknown. Here, <sup>13</sup>C-labeled nutrients were intraoperatively infused into more than 90 surgically resectable pulmonary lesions, metabolic properties of resected tumors correlated survival. In NSCLCs <sup>13</sup>C-glucose, high <sup>13</sup>C enrichment in tricarboxylic acid (TCA) cycle intermediates...
<p>(Related to Figure 1). TCA cycle labeling and metabolite abundance in tumors lungs from NSCLC patents.</p>
<p>(Related to Figure 4). Development of patient-derived xenografts from malignant tumors in the lung.</p>
<p>(Related to Figure 3). TCA cycle metabolite abundance does not correlate with overall survival.</p>
<p>Increased <sup>13</sup>C enrichment in the TCA cycle predicts reduced survival. <b>A,</b><sup>13</sup>C adjacent lung and tumors with high or low labeling. Fractional enrichments of glycolytic (M+3) (M+2) metabolites are normalized to glucose (M+6) within tissue. <b>B</b> <b>C,</b> Overall (<b>B</b>) recurrence-free (<b>C</b>) survival patients whose have The groups include above below median for...
<p>Inhibition of complex I with IACS-010759 limits metastasis in NSCLC PDXs. <b>A</b> and <b>B,</b> Tumor-bearing mice were treated daily DMSO or (5 mg/kg) by oral gavage for 3–4 weeks then infused [U-<sup>13</sup>C]glucose 3 hours. Overall TCA cycle enrichment was calculated as the sum isotopologues citrate, malate, glutamate compared between DMSO- IACS-010759–treated groups. <b>C</b> <b>D,</b> Subcutaneous tumor volume (L ×...
<p>PDXs derived from primary NSCLC retain histological, molecular, and metabolic characteristics. <b>A</b> <b>B,</b> Summary of histological molecular characterization donor tumors (<b>A</b>) PDX models (<b>B</b>). <b>C,</b> H&E staining PDXs. <b>D,</b> Engraftment success NSCLCs lung metastases considering the phenotype patient’s tumor. “High” “low” TCA cycle enrichment was defined in <a href="#fig3"...
<p>PDXs generated from primary NSCLCs spontaneously metastasize in NSG mice. <b>A,</b> Flow cytometry analysis of lung tissue a mouse engrafted with mx73. Cells were stained lineage markers (CD45, CD31, and TER119) HLA. <b>B,</b> Bioluminescence lungs bearing metastases <b>C,</b> IHC staining for Ki67-positive cells metastasis mx148. <b>D,</b> Percentage HLA-ABC–expressing detected the mice NSCLC PDXs. Each dot represents one mouse. Data...
<p>(Related to Figure 2). Epithelial and myeloid cell contributions gene expression 13C labeling features.</p>
<p>(Related to Figure 3). Relationships between TCA cycle labeling and clinical factors.</p>